Clarity is a clinical stage radiopharmaceutical company developing next-generation products to address the growing need for the use of radiopharmaceuticals in oncology. Clarity is a global leader in Targeted Copper Theranostics (TCT), developed with its proprietary SAR Technology platform. TCT are the next-generation disruptive platform in radiopharmaceuticals that employ the "perfect pairing" of copper-64 and copper-67 for diagnosis and therapy. TCT deliver a compelling combination of high accuracy and high precision in the treatment of a range of cancers, as well as providing supply and logistical advantages over current theranostics. TCT provide a highly efficacious, scalable, and cost-effective way to expand radiopharmaceuticals into the global oncology market. Clarity has a diverse range of products in clinical trials which address both large indications (prostate cancer and breast cancer) as well as small and orphan indications (neuroendocrine tumours (NETs) and neuroblastoma) of cancer. Our ultimate goal is to improve treatment outcomes for children and adults with cancer.